Cabozantinib Improves PFS in Patients with Previously Treated, Progressive Advanced Extrapancreatic or Pancreatic Neuroendocrine Tumours By Ogkologos - October 25, 2024 793 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CABINET study Source RELATED ARTICLESMORE FROM AUTHOR Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma FDA Approves Vepdegestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast Cancer Aiming to support a robust regulatory ecosystem for driving cancer research in Europe, ESMO provides feedback to the public consultation on dataset descriptions under... MOST POPULAR FDA Approvals Expand Initial Treatment Options for Multiple Myeloma January 7, 2025 ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ February 3, 2021 FDA Approves Axicabtagene Ciloleucel for Second-Line Treatment of Large B-Cell Lymphoma April 27, 2022 Breast Cancer Survivors Are Still Underrepresented At Victoria’s Secret February 1, 2022 Load more HOT NEWS EMA Recommends Granting a Conditional Marketing Authorisation for Nadofaragene Firadenovec Sotorasib in Combination with Panitumumab Results in Longer PFS in Patients... Body Location May Influence Fate of Cells with Cancer-Causing Mutations Targeted Therapy, Driven by Comprehensive Genomic Profiling and Molecular Tumour Board,...
